Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07684521 · ClinicalTrials.gov registry record · NA
Debriefing Consult for Psychiatric Symptoms After Severe Maternal Morbidity
A NA study, sponsored by Cedars-Sinai Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT07684521: Clinical Trial NA study, sponsored by Cedars-Sinai Medical Center.
NCT07684521 is a NA study that has not yet begun recruiting, run by Cedars-Sinai Medical Center. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07684521, a NA study, has not yet begun recruiting, sponsored by Cedars-Sinai Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if a maternal fetal medicine (MFM) debriefing consult six to eight weeks postpartum reduces self-reported post-traumatic stress, depression, and anxiety symptoms following a delivery complicated by severe maternal morbidity (SMM). Individuals with a delivery complicated an intensive care unit (ICU) admission and/or blood product transfusion \>4 units will be included in this study. Participants will be randomized to an intervention or control group; all participants will complete patient questionnaires that screen for post-traumatic stress disorder, depression, and anxiety. Those in the control group will receive a virtual MFM debriefing consult at six weeks postpartum and those in the intervention group will have the option for a consult at twelve weeks postpartum, after the completion of the questionnaires.
Primary Outcome
Edinburgh Postnatal Depression Scale (EPDS) score
Interventions
- BEHAVIORAL Virtual maternal fetal medicine debriefing consult
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-07 |
| Phase | NA |
What is known before NCT07684521 opens enrollment
NCT07684521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Virtual maternal fetal medicine debriefing consult is the first listed.
NCT07684521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07684521 about?
NCT07684521 is a clinical study titled "Debriefing Consult for Psychiatric Symptoms After Severe Maternal Morbidity". The primary objective of this study is to determine if a maternal fetal medicine (MFM) debriefing consult six to eight weeks postpartum reduces self-reported post-traumatic stress, depression, and anxiety symptoms following a delivery complicated by severe maternal morbidity (SMM). Individuals with ...
What is the current status of trial NCT07684521?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2026-07-01. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07684521?
The interventions under investigation include: Virtual maternal fetal medicine debriefing consult (BEHAVIORAL).
Who is sponsoring clinical trial NCT07684521?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07684521's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI